Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Coronary heart disease (CHD) is one of the most common long-term complications in people with type 2 diabetes. We analyzed whether or not gender differences exist in diabetes and CHD medication among people with type 2 diabetes. Methods: The study was based on data from the baseline examination of the DIANA study, a prospective cohort study of 1,146 patients with type 2 diabetes conducted in South-West Germany. Information on diabetes and CHD medication was obtained from the physician questionnaires. Bivariate and multivariate analyses using logistic regression were employed in order to assess associations between gender and prescribed drug classes. Results: In total, 624 men and 522 women with type 2 diabetes with a mean age of 67.2 and 69.7 years, respectively, were included in this analysis. Compared to women, men had more angiopathic risk factors, including smoking, alcohol consumption and worse glycemic control, and had more often a diagnosed CHD. Bivariate analyses showed higher prescription of thiazolidinediones and oral combination drugs as well as of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers and aspirin in men than in women. After full adjustment, differences between men and women remained significant only for ACE inhibitors (OR = 1.44; 95%-confidence interval (CI): 1.11 – 1.88) and calcium channel blockers (OR = 1.42, 95%-CI: 1.05 – 1.91). Conclusions: These findings contribute to current discussions on gender differences in diabetes care. Men with diabetes are significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers in the presence of coronary heart disease, respectively. Our results suggest, that diabetic men might be more thoroughly treated compared to women. Further research is needed to focus on reasons for these differences mainly in treatment of cardiovascular diseases to improve quality of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“It induces macro- and microvascular damage promoting long-term complications, like coronary heart disease (CHD), stroke or diabetic nephropathy, and is associated with significant morbidity and mortality [1,2].”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
King, D. K., Glasgow, R. E., Toobert, D. J., Strycker, L. A., Estabrooks, P. A., Osuna, D., & Faber, A. J. (2010) · Diabetes Care · doi:10.2337/dc09-1746 · Cited by 369 · cited 1×
“Diabetes and CVD treatment is complex: besides the different applicable agents, disease status, comorbidities, self-management capabilities and individual compliance of patients have to be considered by the treating physicians [5,6].”
BackgroundHeisler, M., Piette, J. D., Spencer, M., Kieffer, E., & Vijan, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.816 · Cited by 326 · cited 1×
“Diabetes and CVD treatment is complex: besides the different applicable agents, disease status, comorbidities, self-management capabilities and individual compliance of patients have to be considered by the treating physicians [5,6].”
Background
Cited by
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60040-4 · Cited by 805
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · Diabetologia · doi:10.1007/s00125-014-3260-6 · Cited by 701
Sex differences in cardiovascular risk factors and disease prevention
Appelman, Y., van Rijn, B. B., ten Haaf, M. E., Boersma, E., & Peters, S. A. E. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.027 · Cited by 588
Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course
Huebschmann, A. G., Huxley, R. R., Kohrt, W. M., Zeitler, P., Regensteiner, J. G., & Reusch, J. E. B. (2019) · Diabetologia · doi:10.1007/s00125-019-4939-5 · Cited by 354
Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., et al. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.4182 · Cited by 288
Metadata
- Authors
- Krämer, H. U., Raum, E., Rüter, G., Schöttker, B., Rothenbacher, D., Rosemann, T., Szecsenyi, J., & Brenner, H.
- Venue
- Cardiovascular Diabetology
- Published
- 2012-07-27
- Volume
- 11
- Issue
- 1
- Pages
- 88-88
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2103802232
- Cited by
- 80
- References
- 6
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study. https://app.cochat.ai/papers/10.1186/1475-2840-11-88
- The paper
- Krämer, H. U., Raum, E., Rüter, G., Schöttker, B., Rothenbacher, D., Rosemann, T., Szecsenyi, J., & Brenner, H. (2012). Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study. Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-11-88
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.